Development of Nipah virus mRNA vaccine

在这项研究中，我们开发并优化了一种稳健、高通量(384孔格式)的ELISA结合试验，以定量Nipah病毒(Niv)融合前(Pre-F)和糖蛋白(G)特异性的血清抗体结合反应。我们还开发和优化了一种重复性很高的基于新城疫慢病毒载体的伪型中和试验，适用于96孔和384孔格式。用Nipah病毒Pre-F或G蛋白免疫恒河猴的血清样本对这些方法进行了优化和验证。然后用这些新城疫病毒EL ISA结合和中和试验来评估新城疫病毒mRNA1215疫苗诱导的血清抗体反应与前F蛋白和单体G蛋白的结合，以及在接种疫苗的非洲绿猴(研究VRC-22-0989)和人类(研究VRC322)中中和新城疫伪型病毒的反应。

For this study we developed and optimized a robust, high-throughput (384-well format) ELISA binding assay to quantify Nipah virus (NiV) pre-fusion (pre-F)- and glycoprotein (G)-specific serum antibody binding responses. We also developed and optimized a highly reproducible NiV lentivirus vector-based pseudo-typed neutralization assay for both 96-well and 384-well formats. Serum samples from rhesus macaques immunized with Nipah virus pre-F or G proteins were used to optimize and validate these assays. These NiV ELISA binding and neutralization assays were then used to assess NiV mRNA-1215 vaccine-induced serum antibody responses for binding to pre-F and monomeric G proteins, and for neutralization of NiV pseudo-typed virus in vaccinated African green monkeys (AGM) (study VRC-22-0989) and humans (study VRC322).